| SC 13D/A | 2024-04-26 | Hanmi Pharmaceutical Co., Ltd. | Aptose Biosciences Inc. | 2,989,415 | 19.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Nantahala Capital Management, LLC | Aptose Biosciences Inc. | 120,132 | 1.5% | EDGAR |
| SC 13D/A | 2024-02-05 | Hanmi Pharmaceutical Co., Ltd. | Aptose Biosciences Inc. | 2,989,415 | - | EDGAR |
| SC 13D | 2023-09-12 | Hanmi Pharmaceutical Co., Ltd. | Aptose Biosciences Inc. | 884,152 | - | EDGAR |
| SC 13G/A | 2023-02-14 | Nantahala Capital Management, LLC | Aptose Biosciences Inc. | 6,052,867 | 6.6% | EDGAR |
| SC 13G | 2023-01-17 | Fletcher Aaron G.L. | Aptose Biosciences Inc. | 3,311,458 | 3.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Nantahala Capital Management, LLC | Aptose Biosciences Inc. | 7,604,693 | 8.5% | EDGAR |
| SC 13G/A | 2022-02-11 | ORBIMED CAPITAL LLC | Aptose Biosciences Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-08-10 | Wilson Donald R. Jr. | Aptose Biosciences Inc. | 8,888,275 | 10.0% | EDGAR |
| SC 13G/A | 2021-02-17 | Consonance Capital Management LP | Aptose Biosciences Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-16 | Consonance Capital Management LP | Aptose Biosciences Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-16 | Consonance Capital Management LP | Aptose Biosciences Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-12 | Nantahala Capital Management, LLC | Aptose Biosciences Inc. | 7,272,673 | 8.2% | EDGAR |
| SC 13G | 2021-02-12 | ORBIMED CAPITAL LLC | Aptose Biosciences Inc. | 8,030,000 | 9.0% | EDGAR |
| SC 13G/A | 2021-02-01 | Wilson Donald R. Jr. | Aptose Biosciences Inc. | 7,972,014 | 9.0% | EDGAR |
| SC 13G/A | 2021-01-15 | Abramson Herbert | Aptose Biosciences Inc. | 3,687,000 | 4.1% | EDGAR |
| SC 13G | 2020-02-14 | Consonance Capital Management LP | Aptose Biosciences Inc. | 4,085,058 | 5.4% | EDGAR |
| SC 13G | 2020-02-14 | Nantahala Capital Management, LLC | Aptose Biosciences Inc. | 6,053,830 | 8.0% | EDGAR |
| SC 13G/A | 2020-02-04 | Abramson Herbert | Aptose Biosciences Inc. | 4,110,000 | 5.6% | EDGAR |
| SC 13G | 2019-12-27 | Opaleye Management Inc. | Aptose Biosciences Inc. | 9 | 11.0% | EDGAR |